Clinical Trial Update: BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating BG00012 (dimethyl fumarate) for delaying disability progression in secondary progressive multiple sclerosis was terminated, with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Secondary Progressive

Drugs mentioned

• BG00012 (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Secondary Progressive | Phase 3 | Status: TERMINATED | Results posted: 2017-03-27